Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation.
Glenmark's Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation has been determined by the FDA to be bioequivalent and therapeutically equivalent1 to the reference listed drug (RLD), FloVent®2 HFA Inhalation Aerosol, 44 mcg of GlaxoSmithKline Intellectual Property Ltd. England (NDA – 021433).
Glenmark has been granted a Competitive Generic Therapy (CGT) designation for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation and is the “first approved applicant' as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act. Therefore, with this approval, Glenmark is eligible for 180 days of CGT exclusivity upon commercialization.
Glenmark's Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA starting in March 2026. The approval further strengthens Glenmark's respiratory portfolio in the U.S. and underscores its commitment to expanding access to quality inhalation therapies.
According to IQVIA sales data for the 12-month period ending January 2026, the FloVent® HFA Inhalation Aerosol, 44 mcg market3 achieved annual sales of approximately $520.1 million.
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis as well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis
Glenmark has also been granted a Competitive Generic Therapy (CGT) designation for the product and has been recognised as the “first approved applicant” under section 505(j)(5)(B)(v)(III) of the FD&C Act. With this approval, the company will be eligible for 180 days of CGT exclusivity upon commercial launch.
The inhalation aerosol will be distributed in the United States by Glenmark Pharmaceuticals Inc., USA starting March 2026. The approval further strengthens Glenmark’s respiratory portfolio in the US and underscores its commitment to expanding access to complex inhalation therapies.
According to IQVIA sales data for the 12-month period ended January 2026, the Flovent HFA Inhalation Aerosol, 44 mcg market recorded annual sales of approximately $520.1 million.
Marc Kikuchi, President & Business Head, North America said, “receiving approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation marks an important milestone in strengthening our respiratory portfolio in the U.S. The CGT designation and first approved applicant status reflect the technical expertise and dedication of our teams in bringing complex inhalation therapies to market. We remain committed to improving access to quality and affordable respiratory treatments for patients and healthcare providers.”
Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.
Glenmark Pharmaceuticals, the company, reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25.
The counter dropped 4.07% to Rs 2,037 on the BSE.
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials.
Glenmark's Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Sodium Phosphates Injection USP, 45 mM P/15 mL (3 mM P/mL), of Hospira, Inc. [NDA 018892], with the 15 mM P/5 mL (3 mM P/mL) and 150 mM P/50 mL (3 mM P/mL) presentations expected to have the same therapeutic effect as that of the listed drug product upon which the FDA relied as the basis of safety and effectiveness.
Glenmark will begin distribution in April 2026.
The company stated that the 15 mM P/5 mL and 150 mM P/50 mL presentations are expected to have the same therapeutic effect as the reference listed drug upon which the US Food and Drug Administration (FDA) relied as the basis for safety and effectiveness.
The pharma company will begin distribution in April 2026.
According to IQVIA sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials market achieved annual sales of approximately $66.8 million.
Marc Kikuchi, president & business head, North America said, “We look forward to the upcoming launch of Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials, strengthening our commitment to bring to market quality and affordable alternatives for patients, while also further expanding our portfolio of products within the institutional channel.”
The company’s consolidated net profit jumped 15.9% to Rs 403.21 crore on 17.8% increase in net sales to Rs 3888 crore in Q3 FY26 over Q3 FY25.
The counter shed 0.20% to Rs 2,122.80 on the BSE.
Glenmark Pharmaceuticals Ltd gained for a third straight session today. The stock is quoting at Rs 2107.3, up 1.07% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 25452.6. The Sensex is at 82117.03, down 0.19%. Glenmark Pharmaceuticals Ltd has gained around 5.38% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 6.36% in last one month and is currently quoting at 23051.85, up 0.53% on the day. The volume in the stock stood at 3.37 lakh shares today, compared to the daily average of 4.7 lakh shares in last one month.
The benchmark March futures contract for the stock is quoting at Rs 2115.8, up 0.94% on the day. Glenmark Pharmaceuticals Ltd is up 60.45% in last one year as compared to a 12.9% jump in NIFTY and a 14.71% jump in the Nifty Pharma index.
The PE of the stock is 39.65 based on TTM earnings ending December 25.
Metal shares extended gains for a fifth consecutive trading session.
At 10:25 ST, the barometer index, the S&P BSE Sensex declined 67.43 points or 0.08% to 85,504.02. The Nifty 50 index advanced 0.10 points or 0.0% to 26,172.75.
In the broader market, the S&P BSE Mid-Cap index shed 0.01% and the S&P BSE Small-Cap index added 0.35%.
The market breadth was weak. On the BSE, 2,220 shares rose and 1,392 shares fell. A total of 237 shares were unchanged.
New Listing:
Shares of KSH International were currently trading at Rs 360.55 at 10:14 IST on the BSE, representing a discount of 6.11% as compared with the issue price of Rs 384.
The stock debuted at Rs 370 on the BSE, exhibiting a discount of 3.65% over the issue price.
So far, the stock has hit a high of 370 and a low of 355. On the BSE, over 3 lakh shares of the company were traded in the counter so far.
Buzzing Index:
The Nifty Metal index jumped 0.62% to 10,735. The index rallied 2.59% in the five consecutive trading sessions.
NMDC (up 2.47%), Hindustan Copper (up 2.43%), Welspun Corp (up 1.78%), Lloyds Metals & Energy (up 1.72%) and Hindustan Zinc (up 1.32%), National Aluminium Company (up 0.95%), Jindal Steel (up 0.76%), Jindal Stainless (up 0.73%), Steel Authority of India (up 0.6%) and Hindalco Industries (up 0.47%) surged.
Stocks in Spotlight:
Antony Waste Handling Cell surged 6.59% after the company announced that its arm, Antony Lara Enviro Solutions, has secured a contract worth Rs 329.45 crore for the development of a mixed solid waste processing plant in Maharashtra.
Glenmark Pharmaceuticals advanced 1.64%. The company said that its wholly owned subsidiary, Glenmark Pharmaceuticals Inc., USA, has announced the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial in the United States.
The company said that its Epinephrine Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) manufactured by BPI Labs, LLC (NDA 205029).
Epinephrine Injection is commonly used in emergency medical settings for the treatment of severe allergic reactions and other critical conditions.
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market recorded annual sales of approximately $67.6 million, indicating a sizeable opportunity in the US generics market.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”
Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25.
Shares of Glenmark Pharmaceuticals rose 0.20% to Rs 2,042.70 on the BSE.